This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

Proving the efficacy of local treatment in liver cancer oligometastases

Proving efficacy of local treatment in liver cancer oligometastases
The inclusion process. Credit: Cancers (2023). DOI: 10.3390/cancers15133467

Professor Chai Hong Rim of the Department of Radiation Oncology, Korea University's Ansan Hospital, along with student Jungsue Lee and Sooyeon Kim of the College of Medicine, Korea University, proved the efficacy of active local treatment such as radiotherapy and radiofrequency ablation (RFA) in liver cancer oligometastases (less than 3 to 5 metastatic foci) through a meta-analysis study.

Liver is being called as a "silent killer" and is a cancer that is very difficult to detect early, because there are no clear symptoms in the early stages. According to the statistics of National Cancer Information Center, has a , ranking the (12.4%) among causes of cancer death. The life expectancy is known to be less than 3 to 6 months when only is performed on metastatic liver cancer.

Although the use of anticancer drugs is generally considered first in the treatment of metastatic cancer, its role had been limited in the treatment of metastatic liver cancer. Not only that, in some cases, active treatment for liver cancer is withdrawn because the role of local treatment, such as radiotherapy and RFA for metastatic lesions has not been sufficiently studied.

Professor Chai Hong Rim's research team performed a systematic literature analysis based on a total of 527 liver cancer oligometastatic patients' data in order to identify the efficacy of local treatment in liver cancer oligometastases.

The analysis showed that the group underwent local treatment, such as radiotherapy and RFA, had significantly improved survival rate compared to the group that did not (Odds Ratio: 4.664, p<0.001). The 1-year and 2-year survival rates for the local treatment group were 71.8% and 43.3%, respectively. Such results were significant higher compared to the for patients with metastatic liver cancer in the literature, after conservative treatment.

Professor Chai Hong Rim of the Department of Radiation Oncology, Korea University's Ansan Hospital said, "Even if liver cancer has already metastasized, the need for local treatment such as radiotherapy and RFA must be evaluated through multidisciplinary treatment in consideration of the degree of metastasis, overall health status, and other physical conditions."

"Recently, local treatment techniques have been improved to minimize side effects, enabling active treatment of metastatic cancer. Also, as the new immunotherapy drugs are being developed that are more effective than previous drugs, such drugs and local treatment can be used together to improve prognosis of patients with metastatic liver cancer."

The result of this research was recently published in Cancers.

More information: Sooyeon Kim et al, Local Treatment of Hepatocellular Carcinoma with Oligometastases: A Systematic Review and Meta-Analysis, Cancers (2023). DOI: 10.3390/cancers15133467

Journal information: Cancers
Provided by Korea University College of Medicine
Citation: Proving the efficacy of local treatment in liver cancer oligometastases (2023, November 2) retrieved 24 February 2024 from https://medicalxpress.com/news/2023-11-efficacy-local-treatment-liver-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Researchers discover resistance to liver cancer treatment

0 shares

Feedback to editors